GLP-1 drugs and Type 1 diabetes: what the evidence says

What did @pushupsnpumps actually say?

Not much, honestly. This video is less a health claim and more a relatable slice of life: a Type 1 diabetic injecting what appears to be a GLP-1 medication late at night, having forgotten their Monday dose, while their cat Pickles stages a small rebellion. The creator mentions priming the pen, confirms "a little bit comes out," and notes the injection is being taken late due to forgetfulness. There are no sweeping medical claims here. That context matters for the fact-check.

The implicit message, though, is that taking a weekly injectable GLP-1 medication a few days late is fine, and that nighttime is an acceptable injection window. Those are the claims worth examining. The creator does not specify which GLP-1 they are using, but the pen-priming technique and weekly cadence suggest semaglutide (Ozempic or Wegovy) or a similar weekly injectable.

Does the science back this up?

On the "late dose" question, yes, with caveats. Semaglutide's half-life is approximately seven days, which is precisely why it is dosed weekly in the first place. Missing a day or two does not create a clinical cliff edge. The FDA prescribing information for Ozempic states that a missed dose can be administered up to five days after the scheduled day. So injecting on Wednesday instead of Monday is within that window.

On nighttime injection: there is no strong pharmacokinetic reason to avoid it. Semaglutide reaches peak plasma concentration roughly 24-48 hours post-injection regardless of time of day (Kristensen et al., 2020, Clinical Pharmacokinetics). Some patients prefer nighttime to blunt the initial nausea wave during sleep, a strategy that has anecdotal support but has not been rigorously tested in randomized trials. The pen-priming step the creator demonstrates is a legitimate and recommended safety practice to confirm needle patency before injection.

What did they get wrong (or right)?

The creator got the practical mechanics right. Priming the pen before injection is explicitly recommended in the manufacturer instructions for use for Ozempic and Wegovy. Confirming that "a little bit comes out" before injecting is exactly what you are supposed to do. That is not a small thing: delivering an air pocket instead of medication is a real user error that skews dosing.

What is worth flagging is the Type 1 diabetes context. GLP-1 receptor agonists are not FDA-approved as standalone treatments for Type 1 diabetes. Their use in T1D is off-label, and the evidence base is genuinely mixed. A 2023 meta-analysis (Shi et al., Diabetes Care) found modest HbA1c reductions in T1D patients using GLP-1 agonists, but also noted increased hypoglycemia risk and diabetic ketoacidosis concerns, particularly with SGLT-2 inhibitors used concurrently. The creator does not address any of this, which is understandable for a 30-second cat video, but viewers with T1D who see the hashtags and assume this is a straightforward recommendation should know the picture is more complicated.

What should you actually know?

If you use a weekly injectable GLP-1 medication and miss your scheduled day, do not panic and do not double-dose. The five-day makeup window for semaglutide is well-established. After that window, skip the missed dose and resume your regular schedule the following week. Always prime your pen. Always.

If you have Type 1 diabetes and are curious about GLP-1 medications, this is a conversation that genuinely requires your endocrinologist, not TikTok. The pharmacology is real, the potential benefits for weight and insulin sensitivity exist, but so do the risks. The American Diabetes Association's 2024 Standards of Care do not include GLP-1 agonists as a standard T1D treatment, which does not make them wrong for every T1D patient, but it does mean the decision needs individualized clinical oversight.

One more thing: the cat priming the injection for you is not a recognized technique and is not covered by any major diabetes organization's guidelines.

Bottom line

This video does not make harmful claims. It shows a real patient doing a real injection with correct technique. The implicit message that a late weekly dose is manageable is accurate. The T1D context adds complexity that the video does not address, and that gap is worth knowing about if you arrived here via the diabetes hashtags.